Tailoring the first line therapy for diffuse large B cell lymphoma

Over the last few decades investigators have tried to beat R-CHOP regimen as front-line treatment of DLBCL. Addition of Ibrutinib or Lenalidomide , intensification of treatment , use of EPOCH regimen with Rituximab have failed to change position of R-CHOP as a standard of care. However, results of recent POLARIX study showed better 2-year Overall Survival for Polatuzumab Vedotin based regimen compared to R-CHOP regimen.